Recent

% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • madmoneyguru madmoneyguru Apr 15, 2013 6:35 PM Flag

    FDA asking for dystrophin because GSK's drug DOESN'T DO IT.

    The FDA is asking for dystrophin as a surrogate endpoing, because the GSK drug doesn't do it and this will directly support AA and rapid approval of eteplirsen. Faster than anybody expects. Watch it happen in 2013.

 
SRPT
13.57+0.50(+3.83%)Mar 27 4:00 PMEDT